Muscle-Invasive Bladder Carcinoma Clinical Trial
Official title:
The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer
The goal of this clinical trial is to evaluate the protective effect of metformin on nephrotoxicity of cisplatin in patients with bladder cancer. The main questions it aims to answer are: - To determine protective effect of metformin on structural and functional kidney injury caused by cisplatin in patients with bladder cancer. - To evaluate the safety of combining cisplatin and metformin on patients with bladder cancer
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05097404 -
Clinical Utility of VI-RADS in Diagnosis of MIBC
|
||
Recruiting |
NCT05483868 -
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
|
Phase 1 | |
Not yet recruiting |
NCT04966130 -
Effect of Urinary Indwelling Time on Early Continence After Robot-assisted Radical Cystectomy With Orthotopic Ileal Neobladder.
|
||
Active, not recruiting |
NCT04610671 -
Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC
|
Phase 1 | |
Recruiting |
NCT06341400 -
RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT05203913 -
Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer
|
Phase 2 | |
Recruiting |
NCT05790850 -
Pre-Habilitation With Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial)
|
N/A | |
Recruiting |
NCT05295992 -
Conventionally Fractionated Adaptive Radiation Therapy of Bladder Cancer an Individualized Approach
|
N/A | |
Recruiting |
NCT05028660 -
AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Study
|
||
Not yet recruiting |
NCT04909775 -
Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer
|
Phase 2 | |
Recruiting |
NCT04876313 -
An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)
|
Phase 2 | |
Not yet recruiting |
NCT04686149 -
a Genome-based Platform to Predict Patients That Can Achieve Bladder Preservation in Muscle Invasive Bladder Cancer Patients
|
||
Active, not recruiting |
NCT05630131 -
ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy
|
||
Recruiting |
NCT06170177 -
Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy
|
||
Terminated |
NCT05221827 -
Clinical Performance Evaluation of the C2i-Test
|
||
Recruiting |
NCT06257017 -
Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: A Pilot Randomized Controlled Trial
|
Phase 2 | |
Recruiting |
NCT05767528 -
Clinical Study of Neoadjuvant Therapy Outcome Prediction of Muscle-invasive Bladder Cancer Based on PTC Drug Sensitivity Detection
|
||
Completed |
NCT04598724 -
Addressing Barriers to Palliative Care Use in Bladder Cancer
|
||
Recruiting |
NCT05975307 -
Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation
|
Phase 2 | |
Suspended |
NCT04506554 -
A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer
|
Phase 2 |